Target intelligence / Profile preview

ETS variant transcription factor 4 (ETV4)

Target
ETV4
Molecular classification
Transcription factor, ETS family
01

Overview

ETS variant transcription factor 4 (ETV4) is a member of the ETS family of transcription factors, particularly the PEA3 subfamily. It functions primarily as a DNA-binding transcriptional activator, playing crucial roles in embryonic development, keratinocyte differentiation, and regulation of cellular proliferation. ETV4 acts as a molecular transducer that links mechanical microenvironments (such as cell crowding) to gene expression, impacting lineage specification in human embryonic stem cells. Pathologically, ETV4 overexpression is associated with several cancers (notably Ewing sarcoma), and it is implicated in cancer progression and resistance to certain therapies via maintenance of MYC expression and modulation of the MAPK signaling pathway. ETV4's expression and function in cancer and stem cell biology make it an important molecular marker and a potential but challenging therapeutic target.

Other names
ETS translocation variant 4ETV4E1AFPEA3Protein PEA3E1A-FAdenovirus E1A enhancer-binding proteinPolyomavirus enhancer activator 3 homologE1A enhancer binding proteinPEAS3EWS protein/E1A enhancer binding protein chimera
02

Mechanism of action

Transcriptional activation of oncogenic and developmental gene targets; Mechanotransduction (mediating response to cell crowding, influencing lineage fate in stem cells); Maintaining MYC expression and promoting therapeutic resistance in multiple myeloma

03

Biological functions

DNA-binding transcription activator activityRNA polymerase II cis-regulatory region sequence-specific DNA bindingPositive regulation of keratinocyte differentiationSignal transduction (MAPK family signaling)Regulation of gene expression during embryonic development and differentiation
04

Disease associations

Cancer (Ewing sarcoma, Extraosseous Ewing's sarcoma)IMiD resistance in multiple myelomaOther: may contribute to mechanism and progression of hemorrhage (intracerebral)
05

Safety considerations

Overexpression associated with oncogenesis, tumor progression, and drug resistanceTargeting transcription factors (such as ETV4) carries risk for broad transcriptional disruption and potential off-target effects
06

Interacting drugs

No clinically approved drugs directly targeting ETV4 are currently known; however, its downstream effects (e.g., MAPK pathway) may be modulated by pathway inhibitors
07

Biomarkers

ETV4 overexpression (biomarker in Ewing sarcoma, other cancers)ETV4 expression pattern for lineage specification in stem cells

Beyond the preview

Go deeper on ETS variant transcription factor 4 (ETV4).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on ETS variant transcription factor 4 (ETV4).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call